HRP20230613T1 - Tableta koja sadrži derivat metoksiureje i čestice manitola - Google Patents
Tableta koja sadrži derivat metoksiureje i čestice manitola Download PDFInfo
- Publication number
- HRP20230613T1 HRP20230613T1 HRP20230613TT HRP20230613T HRP20230613T1 HR P20230613 T1 HRP20230613 T1 HR P20230613T1 HR P20230613T T HRP20230613T T HR P20230613TT HR P20230613 T HRP20230613 T HR P20230613T HR P20230613 T1 HRP20230613 T1 HR P20230613T1
- Authority
- HR
- Croatia
- Prior art keywords
- methoxyurea
- tablet
- film envelope
- tetrahydrothieno
- difluorobenzyl
- Prior art date
Links
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 title claims 11
- 239000002245 particle Substances 0.000 title claims 11
- 235000010355 mannitol Nutrition 0.000 title claims 6
- 229930195725 Mannitol Natural products 0.000 title 1
- 239000000594 mannitol Substances 0.000 title 1
- JOHLTMWXHJLNDE-UHFFFAOYSA-N methoxyurea Chemical class CONC(N)=O JOHLTMWXHJLNDE-UHFFFAOYSA-N 0.000 title 1
- 239000003826 tablet Substances 0.000 claims 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 8
- AOMXMOCNKJTRQP-UHFFFAOYSA-N 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea Chemical compound C1=CC(NC(=O)NOC)=CC=C1C1=C(CN(C)C)C(C(=O)N(C=2N=NC(OC)=CC=2)C(=O)N2CC=3C(=CC=CC=3F)F)=C2S1 AOMXMOCNKJTRQP-UHFFFAOYSA-N 0.000 claims 7
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 5
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims 5
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 4
- 235000019359 magnesium stearate Nutrition 0.000 claims 4
- 239000000843 powder Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229940079832 sodium starch glycolate Drugs 0.000 claims 4
- 229920003109 sodium starch glycolate Polymers 0.000 claims 4
- 239000008109 sodium starch glycolate Substances 0.000 claims 4
- 238000005507 spraying Methods 0.000 claims 3
- 239000008187 granular material Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 1
- 239000007941 film coated tablet Substances 0.000 claims 1
- 239000007888 film coating Substances 0.000 claims 1
- 238000009501 film coating Methods 0.000 claims 1
- 238000007873 sieving Methods 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (10)
1. Tableta koja sadrži:
N-(4-(1-(2,6-difluorobenzil)-5-((dimetilamino)metil)-3-(6-metoksi-3-piridazinil)-2,4-diokso-1,2,3,4-tetrahidrotieno[2,3-d]pirimidin-6-il)fenil)-N'-metoksiureju ili njezinu sol u količini od 40 mg mjereno na temelju slobodnog oblika N-(4-(1-(2,6-difluorobenzil)-5-((dimetilamino)metil)-3-(6-metoksi-3-piridazinil)-2,4-diokso-1,2,3,4-tetrahidrotieno[2,3-d]pirimidin-6-il)fenil)-N'-metoksiureje,
51 mg čestica D-manitola koje imaju prosječnu veličinu čestica od 70 - 200 µm,
5 mg natrijevog škrobnog glikolata,
3 mg hidroksipropilceluloze, i
1 mg magnezijevog stearata.
2. Tableta prema zahtjevu 1, naznačena time što dodatno sadrži filmsku ovojnicu, pri čemu filmska ovojnica sadrži hidroksipropilmetilcelulozu, titanijev oksid i crveni željezov oksid.
3. Tableta prema zahtjevu 1, naznačena time što dodatno sadrži filmsku ovojnicu, pri čemu filmska ovojnica sadrži 3,56 mg hidroksipropilmetilceluloze, 0,40 mg titanijevog oksida i 0,04 mg crvenog željezovog oksida.
4. Tableta koja sadrži:
N-(4-(1-(2,6-difluorobenzil)-5-((dimetilamino)metil)-3-(6-metoksi-3-piridazinil)-2,4-diokso-1,2,3,4-tetrahidrotieno[2,3-d]pirimidin-6-il)fenil)-N'-metoksiureju ili njezinu sol u količini od 120 mg mjereno na temelju slobodnog oblika N-(4-(1-(2,6-difluorobenzil)-5-((dimetilamino)metil)-3-(6-metoksi-3-piridazinil)-2,4-diokso-1,2,3,4-tetrahidrotieno[2,3-d]pirimidin-6-il)fenil)-N'-metoksiureje,
153 mg čestica D-manitola koje imaju prosječnu veličinu čestica od 70 - 200 µm,
15 mg natrijevog škrobnog glikolata,
9 mg hidroksipropilceluloze, i
3 mg magnezijevog stearata.
5. Tableta prema zahtjevu 4, naznačena time što dodatno sadrži filmsku ovojnicu, pri čemu filmska ovojnica sadrži hidroksipropilmetilcelulozu, titanijev oksid i crveni željezov oksid.
6. Tableta koja sadrži:
N-(4-(1-(2,6-difluorobenzil)-5-((dimetilamino)metil)-3-(6-metoksi-3-piridazinil)-2,4-diokso-1,2,3,4-tetrahidrotieno[2,3-d]pirimidin-6-il)fenil)-N'-metoksiureju ili njezinu sol u količini od 80 mg mjereno na temelju slobodnog oblika N-(4-(1-(2,6-difluorobenzil)-5-((dimetilamino)metil)-3-(6-metoksi-3-piridazinil)-2,4-diokso-1,2,3,4-tetrahidrotieno[2,3-d]pirimidin-6-il)fenil)-N'-metoksiureje,
102 mg čestica D-manitola koje imaju prosječnu veličinu čestica od 70 - 200 µm,
10 mg natrijevog škrobnog glikolata,
6 mg hidroksipropilceluloze, i
2 mg magnezijevog stearata.
7. Tableta prema zahtjevu 6, naznačena time što dodatno sadrži filmsku ovojnicu, pri čemu filmska ovojnica sadrži hidroksipropilmetilcelulozu, titanijev oksid i crveni željezov oksid.
8. Tableta prema zahtjevu 6, naznačena time što dodatno sadrži filmsku ovojnicu, pri čemu filmska ovojnica sadrži 7,12 mg hidroksipropilmetilceluloze, 0,80 mg titanijevog oksida i 0,08 mg crvenog željezovog oksida.
9. Tableta prema bilo kojem od zahtjeva 1-8, naznačena time što čestice D-manitola imaju prosječnu veličinu čestica od 75 - 150 µm.
10. Postupak za izradu tablete prema bilo kojem od zahtjeva 1, 4 ili 6, naznačen time što navedeni postupak obuhvaća:
1) miješanje N-(4-(1-(2,6-difluorobenzil)-5-((dimetilamino)metil)-3-(6-metoksi-3-piridazinil)-2,4-diokso-1,2,3,4-tetrahidrotieno[2,3-d]pirimidin-6-il)fenil)-N'-metoksiureje ili njezine soli s česticama D-manitola koje imaju prosječnu veličinu čestica od 70 - 200 µm i natrijevog škrobnog glikolata;
2) raspršivanje u smjesu iz koraka 1) otopine hidroksipropilceluloze u otapalu ili mediju za raspršivanje;
3) sušenje ili prosijavanje smjese iz koraka 2) da se dobije granulirani prah ili prosijani prah;
4) dodavanje magnezijevog stearata u granulirani prah ili prosijani prah iz koraka 3) i miješanje da se dobiju granule za tabletiranje;
5) tabletiranje granula iz koraka 4) da se dobije jezgra tablete; i, izborno,
6) raspršivanje otopine za oblaganje filmom na jezgru tablete iz koraka 5) kako bi se dobila tableta obložena filmom.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015037462 | 2015-02-26 | ||
| PCT/JP2016/055540 WO2016136849A1 (ja) | 2015-02-26 | 2016-02-25 | 固形製剤 |
| EP16755593.7A EP3263110B1 (en) | 2015-02-26 | 2016-02-25 | A tablet comprising a methoxyurea derivative and mannitol particles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230613T1 true HRP20230613T1 (hr) | 2023-09-29 |
Family
ID=56789547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230613TT HRP20230613T1 (hr) | 2015-02-26 | 2016-02-25 | Tableta koja sadrži derivat metoksiureje i čestice manitola |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10350170B2 (hr) |
| EP (2) | EP4233847A1 (hr) |
| JP (1) | JP6730978B2 (hr) |
| CN (1) | CN107249590A (hr) |
| AU (1) | AU2016224503B2 (hr) |
| BR (1) | BR112017018173A2 (hr) |
| CA (1) | CA2978223A1 (hr) |
| CY (1) | CY1126118T1 (hr) |
| DK (1) | DK3263110T3 (hr) |
| ES (1) | ES2950995T3 (hr) |
| FI (1) | FI3263110T3 (hr) |
| HR (1) | HRP20230613T1 (hr) |
| HU (1) | HUE062269T2 (hr) |
| IL (1) | IL254132B (hr) |
| LT (1) | LT3263110T (hr) |
| MX (1) | MX2017010945A (hr) |
| MY (1) | MY180680A (hr) |
| PL (1) | PL3263110T3 (hr) |
| PT (1) | PT3263110T (hr) |
| RS (1) | RS64377B1 (hr) |
| SI (1) | SI3263110T1 (hr) |
| TW (1) | TWI744224B (hr) |
| WO (1) | WO2016136849A1 (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2900675B1 (en) | 2012-09-28 | 2019-03-06 | Takeda Pharmaceutical Company Limited | Production method of thienopyrimidine derivative |
| MX2019003733A (es) * | 2016-09-30 | 2019-09-26 | Myovant Sciences Gmbh | Tratamiento de cancer de prostata. |
| HRP20220708T1 (hr) | 2016-09-30 | 2022-07-22 | Myovant Sciences Gmbh | Postupci liječenja fibroida maternice i endometrioze |
| WO2019178304A1 (en) | 2018-03-14 | 2019-09-19 | Teva Pharmaceuticals International Gmbh | Solid state forms of relugolix |
| CA3145993A1 (en) | 2019-08-02 | 2021-02-11 | Johnson Matthey Public Limited Company | Solid-state forms of relugolix |
| WO2021230308A1 (ja) | 2020-05-15 | 2021-11-18 | 塩野義製薬株式会社 | 不純物の生成を抑制した医薬組成物 |
| KR20230028732A (ko) | 2020-05-29 | 2023-03-02 | 마이오반트 사이언시즈 게엠베하 | 고나도트로핀 방출 호르몬 길항제의 복합 고형 경구 투여 형태 |
| JP2023549196A (ja) | 2020-11-11 | 2023-11-22 | ミオバント サイエンシズ ゲーエムベーハー | レルゴリクスの投与方法 |
| WO2023066941A1 (en) | 2021-10-18 | 2023-04-27 | Myovant Sciences Gmbh | Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| CN115671069A (zh) * | 2022-11-24 | 2023-02-03 | 北京鑫开元医药科技有限公司 | 一种瑞卢戈利片剂及其制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW284688B (hr) * | 1991-11-20 | 1996-09-01 | Takeda Pharm Industry Co Ltd | |
| FR2710637B1 (fr) * | 1993-09-28 | 1995-12-08 | Roquette Freres | Mannitol pulvérulent de friabilité modérée et son procédé de préparation. |
| TW449600B (en) | 1994-04-19 | 2001-08-11 | Takeda Chemical Industries Ltd | Condensed-ring thiophene derivatives, their production and use |
| JP3854648B2 (ja) * | 1994-04-19 | 2006-12-06 | 武田薬品工業株式会社 | 縮合チオフェン誘導体、その製造法及び用途 |
| TWI225863B (en) | 1999-03-24 | 2005-01-01 | Takeda Chemical Industries Ltd | Thienopyrimidine compounds, their production and use |
| WO2003064429A1 (fr) | 2002-01-30 | 2003-08-07 | Takeda Chemical Industries, Ltd. | Thienopyrimidines, procedes de fabrication et d'utilisation correspondants |
| JP5072166B2 (ja) * | 2002-01-30 | 2012-11-14 | 武田薬品工業株式会社 | チエノピリミジン化合物、その製造法および用途 |
| BRPI0307786B8 (pt) * | 2002-02-26 | 2021-05-25 | Astrazeneca Ab | composição farmacêutica, método para preparar a mesma, métodos para inibir a taxa de precipitação do agente da solução no trato gi, e para reduzir variabilidade inter-pacientes no que se refere à biodisponibilidade e/ou concentrações plásmáticas do agente, e, uso de um celulose éter solúvel em água ou de um éster de um celulose éter solúvel em água |
| JP4039574B2 (ja) * | 2003-01-29 | 2008-01-30 | 武田薬品工業株式会社 | チエノピリミジン化合物およびその用途 |
| AU2004207706B2 (en) | 2003-01-29 | 2010-03-04 | Takeda Pharmaceutical Company Limited | Thienopyrimidine compounds and use thereof |
| JP2006035365A (ja) * | 2004-07-26 | 2006-02-09 | Hitachi Koki Co Ltd | 携帯用切断工具 |
| WO2010026993A1 (ja) | 2008-09-03 | 2010-03-11 | 武田薬品工業株式会社 | 製剤における吸収性改善方法および吸収性が改善された製剤 |
| JP2015037462A (ja) | 2012-06-01 | 2015-02-26 | 株式会社コナミデジタルエンタテインメント | ゲーム装置、ゲーム方法、及びプログラム |
| EP2900675B1 (en) | 2012-09-28 | 2019-03-06 | Takeda Pharmaceutical Company Limited | Production method of thienopyrimidine derivative |
| JOP20200097A1 (ar) * | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
-
2016
- 2016-02-25 HU HUE16755593A patent/HUE062269T2/hu unknown
- 2016-02-25 US US15/553,852 patent/US10350170B2/en active Active
- 2016-02-25 AU AU2016224503A patent/AU2016224503B2/en active Active
- 2016-02-25 MX MX2017010945A patent/MX2017010945A/es active IP Right Grant
- 2016-02-25 MY MYPI2017702655A patent/MY180680A/en unknown
- 2016-02-25 DK DK16755593.7T patent/DK3263110T3/da active
- 2016-02-25 BR BR112017018173-8A patent/BR112017018173A2/pt not_active Application Discontinuation
- 2016-02-25 SI SI201631725T patent/SI3263110T1/sl unknown
- 2016-02-25 TW TW105105637A patent/TWI744224B/zh active
- 2016-02-25 PL PL16755593.7T patent/PL3263110T3/pl unknown
- 2016-02-25 EP EP23172275.2A patent/EP4233847A1/en active Pending
- 2016-02-25 RS RS20230582A patent/RS64377B1/sr unknown
- 2016-02-25 WO PCT/JP2016/055540 patent/WO2016136849A1/ja active Application Filing
- 2016-02-25 ES ES16755593T patent/ES2950995T3/es active Active
- 2016-02-25 CN CN201680012266.5A patent/CN107249590A/zh active Pending
- 2016-02-25 EP EP16755593.7A patent/EP3263110B1/en active Active
- 2016-02-25 FI FIEP16755593.7T patent/FI3263110T3/fi active
- 2016-02-25 LT LTEPPCT/JP2016/055540T patent/LT3263110T/lt unknown
- 2016-02-25 HR HRP20230613TT patent/HRP20230613T1/hr unknown
- 2016-02-25 CA CA2978223A patent/CA2978223A1/en active Pending
- 2016-02-25 JP JP2017502452A patent/JP6730978B2/ja active Active
- 2016-02-25 PT PT167555937T patent/PT3263110T/pt unknown
-
2017
- 2017-08-24 IL IL254132A patent/IL254132B/en active IP Right Grant
-
2019
- 2019-06-05 US US16/432,091 patent/US20200000730A1/en not_active Abandoned
-
2023
- 2023-07-28 CY CY20231100374T patent/CY1126118T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN107249590A (zh) | 2017-10-13 |
| RS64377B1 (sr) | 2023-08-31 |
| ES2950995T3 (es) | 2023-10-17 |
| MX2017010945A (es) | 2018-07-06 |
| CY1126118T1 (el) | 2023-11-15 |
| DK3263110T3 (da) | 2023-07-31 |
| AU2016224503A1 (en) | 2017-09-14 |
| LT3263110T (lt) | 2023-07-10 |
| US20180036250A1 (en) | 2018-02-08 |
| MY180680A (en) | 2020-12-06 |
| EP4233847A1 (en) | 2023-08-30 |
| PL3263110T3 (pl) | 2023-11-06 |
| PT3263110T (pt) | 2023-08-01 |
| EP3263110A4 (en) | 2018-11-07 |
| EP3263110B1 (en) | 2023-05-10 |
| WO2016136849A1 (ja) | 2016-09-01 |
| HUE062269T2 (hu) | 2023-10-28 |
| TW201639575A (zh) | 2016-11-16 |
| JPWO2016136849A1 (ja) | 2017-12-07 |
| IL254132B (en) | 2020-02-27 |
| FI3263110T3 (fi) | 2023-07-25 |
| EP3263110A1 (en) | 2018-01-03 |
| JP6730978B2 (ja) | 2020-07-29 |
| NZ735026A (en) | 2021-09-24 |
| AU2016224503B2 (en) | 2021-07-08 |
| US10350170B2 (en) | 2019-07-16 |
| BR112017018173A2 (pt) | 2018-04-10 |
| IL254132A0 (en) | 2017-10-31 |
| SI3263110T1 (sl) | 2023-09-29 |
| CA2978223A1 (en) | 2016-09-01 |
| TWI744224B (zh) | 2021-11-01 |
| US20200000730A1 (en) | 2020-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230613T1 (hr) | Tableta koja sadrži derivat metoksiureje i čestice manitola | |
| JP2018021082A5 (hr) | ||
| HRP20200037T1 (hr) | TABLETA KOJA SADRŽI 7-[4- (4-BENZO [b] TIOFEN-4-YL-PIPERAZIN-1-YL) BUTOKSI]-1H-KINOLIN-2-ON ILI NJEGOVU SOL | |
| RU2016123828A (ru) | Комбинированная композиция для перорального введения, содержащая эзетимиб и розувастатин | |
| JP6402191B2 (ja) | コリンアルホスセラートを含有するフィルムコーティング錠剤およびその製造方法 | |
| JP2015511635A5 (hr) | ||
| TWI700100B (zh) | 用於口服投藥之包含依澤替米貝（ｅｚｅｔｉｍｉｂｅ）及羅舒伐他汀（ｒｏｓｕｖａｓｔａｔｉｎ）的複合調配物及其製備方法 | |
| JP2015533164A5 (hr) | ||
| JP6183979B2 (ja) | アリピプラゾール無水物を含有する固形製剤の製造方法 | |
| RU2014119866A (ru) | Твердые дозированные формы (s)-этил 2-амино-3-(2-амино-6(r)-1-(4-хлор-2-(3-метил-1н-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропаноата | |
| JP6243265B2 (ja) | ロスバスタチン含有医薬製剤 | |
| JP2016033133A5 (hr) | ||
| JP5047572B2 (ja) | 臭いの防止された固形医薬製剤の製造方法、及びそれにより得られる固形医薬製剤 | |
| JP2015120758A5 (hr) | ||
| JP2017101021A (ja) | テルミサルタンを有効成分として含有するフィルムコーティング錠 | |
| JP2015221782A5 (hr) | ||
| JP2017520619A5 (hr) | ||
| JP2017515880A5 (hr) | ||
| JP2016013980A5 (hr) | ||
| EA033291B1 (ru) | Единица дозирования, содержащая рамиприл и бисопролола гемифумарат, способ ее получения и способ лечения гипертензии | |
| RU2018100755A (ru) | Комбинированный препарат мозаприда и рабепразола | |
| JP6741117B2 (ja) | 固形製剤 | |
| JP2017095441A (ja) | アジルサルタン含有医薬組成物、医薬組成物におけるアジルサルタンの安定化方法、及びアジルサルタンの安定化剤 | |
| JP5934835B2 (ja) | 腸溶性細粒及び医薬組成物 | |
| JP2016069382A5 (hr) |